Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Cellectar Biosciences Inc (CLRB)

Cellectar Biosciences Inc (CLRB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Cellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026 GlobeNewswire - Tue Apr 21, 9:00AM CDT

FLORHAM PARK, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for...

CLRBZ : 0.12 (-14.27%)
CLRB : 2.53 (-1.17%)
CLRBW : 0.13 (+348.28%)
Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC) GlobeNewswire - Tue Apr 14, 7:35AM CDT

FLORHAM PARK, N.J., April 14, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for...

CLRBZ : 0.12 (-14.27%)
CLRB : 2.53 (-1.17%)
CLRBW : 0.13 (+348.28%)
Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates GlobeNewswire - Wed Mar 4, 6:15AM CST

On track to submit Conditional Marketing Authorization for iopofosine I 131 to European Medicines Agency in Q3 2026 for potential 2027 EU commercialization as a treatment for Waldenström Macroglobulinemia...

CLRBZ : 0.12 (-14.27%)
CLRB : 2.53 (-1.17%)
CLRBW : 0.13 (+348.28%)
Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026 GlobeNewswire - Wed Feb 25, 7:05AM CST

FLORHAM PARK, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for...

CLRBZ : 0.12 (-14.27%)
CLRB : 2.53 (-1.17%)
CLRBW : 0.13 (+348.28%)
Cellectar Biosciences Expands Global Intellectual Property Estate GlobeNewswire - Tue Feb 17, 7:05AM CST

Strengthens Protection Around Broad Portfolio of Cancer-Targeting Drug Conjugates and Enabling Technologies Provides Key Coverage Across Europe Ahead of Planned 3Q26 Filing for Conditional Marketing...

CLRBZ : 0.12 (-14.27%)
CLRB : 2.53 (-1.17%)
CLRBW : 0.13 (+348.28%)
Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference GlobeNewswire - Fri Jan 9, 7:05AM CST

Following Guidance from the European Medicines Agency’s (EMA) Scientific Advice Working Party (SAWP) Regarding Iopofosine I 131 for the Treatment of Waldenstrom’s Macroglobulinemia (WM), Expects to...

CLRBZ : 0.12 (-14.27%)
CLRB : 2.53 (-1.17%)
CLRBW : 0.13 (+348.28%)
Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies GlobeNewswire - Tue Dec 16, 2025

FLORHAM PARK, N.J. and LANSING, Mich., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development...

CLRBZ : 0.12 (-14.27%)
CLRB : 2.53 (-1.17%)
CLRBW : 0.13 (+348.28%)
Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update GlobeNewswire - Thu Nov 13, 2025

Expects to Submit Conditional Marketing Approval Application in Europe for Iopofosine I 131 in Refractory (post-BTKi) Waldenstrom’s Macroglobulinemia in 2026 Following Advice and Guidance from Scientific...

CLRBZ : 0.12 (-14.27%)
CLRB : 2.53 (-1.17%)
CLRBW : 0.13 (+348.28%)
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025 GlobeNewswire - Thu Nov 6, 2025

FLORHAM PARK, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for...

CLRBZ : 0.12 (-14.27%)
CLRB : 2.53 (-1.17%)
CLRBW : 0.13 (+348.28%)
Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma GlobeNewswire - Mon Oct 27, 2025

FLORHAM PARK, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for...

CLRBZ : 0.12 (-14.27%)
CLRB : 2.53 (-1.17%)
CLRBW : 0.13 (+348.28%)

Barchart Exclusives

Dear Western Digital Stock Fans, Mark Your Calendars for April 30 Barchart - 1 minute ago
The upcoming Q3 earnings report is another stock upside catalyst for Western Digital. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.